spacer
home > ebr > summer 2002 > gene therapy for damaged nerves
PUBLICATIONS
European Biopharmaceutical Review

Gene Therapy for Damaged Nerves

It has long been recognised that cells from the peripheral nervous system (PNS) can regenerate. In contrast, the adult brain and spinal cord (or central nervous system [CNS]) does not regenerate under normal conditions. This poses major problems to patients and their neurologists, as there are currently no treatments available to promote regeneration of injured brain or spinal cord tissue.The study of the fundamental cellular and molecular mechanisms that underlie successful regeneration in the PNS (and its failure in the CNS) form the overall objective of the neuroregeneration team at the Netherlands Institute for Brain Research (NIBR) in Amsterdam. Headed by Professor Joost Verhaagen, the group is investigating strategies to promote neuroregeneration and axonal outgrowth. These could then be employed in the treatment of spinal cord injuries and also neurodegenerative diseases such as Alzheimer's.One approach employed by the team is gene therapy, using viral vectors to deliver genes that are functional or up-regulated in regenerating PNS tissue to brain or spinal cord tissue that does not re-grow. Gene therapy is still a relatively young science - the first human gene therapy trials began in 1990 using an ex vivo method.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Andreas Rьhlmann, European Bioinformatics and Microarray Specialist at Agilent Technologies

Dr Andreas Rьhlmann studied Physics and Chemistry at the University of Hamburg and Gцttingen and holds a degree in Organic Chemistry and a doctorate in Biochemistry from the University of Gцttingen/University of Braunschweig.
He worked as a Research Scientist at Harvard Medical School, Hannover Medical School and at the University of Tьbingen, mainly on gene regulation and signal transduction, as well as in clinical chemistry at the University of Magdeburg. He joined Agilent in June 2000 and serves as a European Bioinformatics and Microarray Specialist.

spacer
Dr Andreas Rьhlmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Why You Should Be Using Ultrasonic Cleaning

Natoli Engineering Company, Inc.

Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling. The Tableting Specification Manual (TSM) states, “An ultrasonic bath is ideal for cleaning tooling.” This high-tech cleaning process also saves time, reduces cost and is better for the environment.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement